SEATTLE–(BUSINESS WIRE)–Organic Monod, a life sciences company developing custom diagnostic biosensors that emit light to detect specific biomolecules of interest, announced today that it has raised $25 million in seed funding. The round was led by Matrix Capital, with participation from Global Health Investment Corporation, Cercano Management, The Washington Research Foundation, Boom Capital Ventures, Sahsen Ventures and Pack Ventures.
Monod uses state-of-the-art computational protein design to develop a new class of modular biosensors that emit a bioluminescent signal when the sensor recognizes its target. Biosensors are instruments that detect the presence of specific molecules, even in trace amounts. The sensors are constructed from de novo modified proteins developed using software from the Institute of Protein Design (IPD) at the University of Washington School of Medicine.
The company’s biosensor platform unites binding, transduction and amplification in a single step, enabling the detection of a wide range of target molecules such as biomarkers, viruses and toxins. Monod has so far created biosensors that recognize the spike protein of the COVID-19 virus, cancer receptors and a molecule (cardiac troponin), which is released by the body after a heart attack, which was published in Nature. More recently, this technology has been applied to the detection of neutralizing antibodies to COVID-19 in vaccinated patients, Natural biotechnology.
The new funding will be used to advance Monod’s LucCage platform for the rapid development of one-step biosensors and reporter proteins to detect targets for applications in biotechnology and medicine. LucCage owner of Monod combines breakthrough technologies in engineering, biology and machine learning to create custom biosensors from scratch with unparalleled consistency and very low costs. The company plans to double the size of its research and engineering teams in the next 18 months.
Monod was founded in November 2021 from technology developed in the lab of David Baker at the University of Washington’s Institute for Protein Design. The company was co-founded by Daniel-Adriano Silva, Ph.D., CEO, Alfredo Quijano Rubio, Ph.D, Scientific Director, David Shoultz, Ph.D., MBA, Chief Operating Officer, and David Baker, Scientific Advise.
“We can now design custom biosensors that have specific functions, and this seed funding allows us to shine a light on specific molecules such as viruses or biomarkers, and start building prototypes that can then become diagnostics of the world. real,” said Daniel-Adriano Silva, Ph.D., CEO and Co-Founder, Monod Bio. “I am excited to lead a team with my co-founders that brings together diverse backgrounds in biology, protein engineering, and machine learning to design personalized biosensors and improve human health.”
“We know that these new biosensors can easily detect viral proteins or antibodies in simulated nasal fluid or donated serum. Our next goal is to ensure that they can be used reliably in a diagnostic context. Monod Bio’s work illustrates the power of de novo protein design to create molecular devices from scratch with useful new functions,” said David Baker, Ph.D., Henrietta and Aubrey Davis Professor of Biochemistry at the Washington University School of Medicine. , researcher at the Howard Hughes Medical Institute, co-founder of Monod Bio, and founder and director of IPD.
“LucCage is a breakthrough platform for biosensor development, and we are excited to have the support of leading investors to advance our team and our technology,” said Alfredo Quijano Rubio, Ph.D, Director scientist, co-founder and main inventor of Monod’s LucCage Technology.
“Monod uses synthetic biology to leverage the architecture of living organisms to achieve high sensitivity and high detection accuracy at scale, due to the low costs of biosensors compared to conventional laboratory tests,” said said Karan Takhar, Managing Partner, Matrix Capital. “Our partnership with Monod Bio reflects our commitment to supporting extraordinary teams unlocking disruptive innovation at the intersection of technology and life sciences.”
“Monod is taking advantage of recent advances in computational protein engineering and is at the forefront of creating highly modular biosensors to develop rapid, sensitive and cost-effective analytical tests,” said Damien Soghoian, Partner, Global Health Investment Corporation. “With a visionary founding team and IPD’s cutting-edge technology, Monod Bio is well positioned at the forefront of biosensor innovation and has the experience and vision to make it a reality.”
About Monod Bio
Monod Bio is a pioneer in the design of de novo personalized protein-based biosensors that emit light when they recognize their target. Monod Bio’s innovative biosensor platform technology uses protein computational engineering to create highly modular biosensing nanoswitches that enable rapid, sensitive and cost-effective analytical assays. The company is based on technology developed in the group of David Baker at the Institute for Protein Design at the University of Washington. Monod has been published in several peer-reviewed journals, including Nature and Natural biotechnology, shaping our understanding of scalable digital healthcare solutions. Monod Bio is based in Seattle, WA. For more information, visit www.monodbio.com.